Effects of heart rate reduction with ivabradine on the international ındex of erectile function (IIEF-5) in patients with heart failure

Figures & data

Table 1. Changes in laboratuary findings, IEFF-5 scores, heart rate (HR), ejection fractions (EF) and blood pressures between baseline and 6 month after the ivabradine treatment.

	Baseline (mean)	6 month (mean)	p value
IEFF-5 Score	13.5 ± 3.6	15.1 ± 3.9	.003
HR (bpm)	87.6 ± 11.0	76.2 ± 7.9	<.001
EF (%)	25.5 ± 6.0	26.8 ± 4.8	.082
SBP (mmHg)	116.4 ± 19.5	119.9 ± 15.6	.273
DBP (mmHg)	70.0 ± 12,2	73.4 ± 10.9	.057
Hgb	12.9 ± 1.9	12.9 ± 1.7	.955
WBC	8103.6 ± 2038	8291.4 ± 2416	.589
Plt	245.7 ± 91.8	241.0 ± 85.7	.405
Na	139.7 ± 4.0	139.1 ± 4.3	.398
K	4.7 ± 0.6	4.6 ± 0.5	.715
BUN	28.8 ± 18.2	30.5 ± 16.4	.316
Cre	1.18 ± 0.53	1.21 ± 0.52	.495

BUN: blood urine nitrogen; Cre: creatinine; DBP: diastolic blood pressure; EF: ejection fraction; Hgb: hemoglobulin; HR: heart rate; IEFF: International Index of Erectile Function; K: potassium; Na: sodium; Plt: platelet; SBP: systolic blood pressure; WBC: white blood cells.

Figure 1. Changes between baseline and 6 month after the ivabradine treatment according to IEFF-5 scores and heart rate.

Table 2. Changes in IEFF score grades between baseline an 6 month after the ivabradine treatment.

IEFF score grade	Baseline (n)	6 month (n)	p value
None (22–25)	0	1	.096
Mild (17–21)	7	6
Mild–moderate (12–16)	8	11
Moderate (8–11)	6	4
Severe (5–7)	1	0

IEFF: International Index of Erectile Function.

Table 3. IEFF-5 score and HR changes according to concomitant diseases and treatments.

	Baseline IEFF-5 score	6 Month IEFF-5 score	p value	Baseline HR	6 Month HR	p value
DM^a (n:8)	12.9 ± 3.7	13.4 ± 4.0	.470	85.5 ± 10,9	75.8 ± 5.5	.031
HT^a (n:16)	13.9 ± 3.8	15.5 ± 4.1	.009	86.8 ± 10.5	75.0 ± 7.0	<.001
HPL^a (n:9)	13.1 ± 4.2	14.9 ± 3.6	.039	88.9 ± 12.7	73.6 ± 5.8	.006
Smoker^a (n:7)	15.1 ± 3.6	17.6 ± 4.1	.021	85.7 ± 8.8	73.7 ± 7.9	.006
ACE/ARB^b (n:17)	13.7 ± 3.7	15.4 ± 4.3	.006	87.9 ± 11.2	76.7 ± 8.4	<.001
B blocker^b (n:14)	14.6 ± 3.4	16.4 ± 3.5	.008	90.0 ± 12.4	76.6 ± 7.5	<.001
Loop diuretics^b (n:18)	13.6 ± 3.9	15.5 ± 3.7	.002	86.6 ± 10.0	74.4 ± 7.1	<.001
Spironolactone^b (n:14)	13.6 ± 4.0	15.9 ± 4.1	.002	89.3 ± 12.8	75.1 ± 8.5	<.001
Nitrate^b (n:6)	11.2 ± 4.1	14.2 ± 4.3	.005	88.7 ± 12.2	78.0 ± 9.1	.013

^aConcomitant diseases.

^bTreatments.

ACE/ARB: anjiotensine converting enzym inhibitors/anjiotensinogen reseptör antagonists; DM: diabetes mellitus; HT: hypertension; HPL: hyperlipidemia; HR: heart rate; IEFF: International Index of Erectile Function.